These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34404223)

  • 1. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
    Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
    Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
    Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
    Marco-Benedí V; Sánchez-Hernández RM; Díaz JL; Jarauta E; Suárez-Tembra M; Pintó X; Morillas C; Plana N; Pedro-Botet J; Civeira F
    Lipids Health Dis; 2024 Sep; 23(1):290. PubMed ID: 39256734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
    Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
    J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
    Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
    Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
    Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
    J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.
    Hollstein T; Kassner U; Grenkowitz T; Schumann F; Bobbert T; Steinhagen-Thiessen E
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):83-92. PubMed ID: 32514867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
    Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
    Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.